Evidence map›Paper›PMID 36302655›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2023

Preclinical Evaluation of

Olli Moisio, Jenni Virta, Emrah Yatkin, Heidi Liljenbäck, Senthil Palani, Riikka Viitanen, Maxwell W G Miner, Vesa Oikonen, Tuula Tolvanen, Danielle J Vugts and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. EJNMMI radiopharmacy and chemistry · 2023
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Olli MoisioTurku PET Centre, University of Turku, Turku, Finland.
Jenni VirtaTurku PET Centre, University of Turku, Turku, Finland.
Emrah YatkinCentral Animal Laboratory, University of Turku, Turku, Finland.
Heidi LiljenbäckTurku PET Centre, University of Turku, Turku, Finland.
Senthil PalaniTurku PET Centre, University of Turku, Turku, Finland.
Riikka ViitanenTurku PET Centre, University of Turku, Turku, Finland.
Maxwell W G MinerTurku PET Centre, University of Turku, Turku, Finland.
Vesa OikonenTurku PET Centre, University of Turku, Turku, Finland.
Tuula TolvanenTurku PET Centre, Turku University Hospital, Turku, Finland.
Danielle J VugtsDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, VU University, Amsterdam, The Netherlands.
Pekka TaimenInstitute of Biomedicine, University of Turku, and Department of Pathology, Turku University Hospital, Turku, Finland.
Xiang-Guo LiTurku PET Centre, University of Turku, Turku, Finland.
Maija HollménInFLAMES Research Flagship Center, University of Turku, Turku, Finland.
Sirpa JalkanenInFLAMES Research Flagship Center, University of Turku, Turku, Finland.
Anne RoivainenTurku PET Centre, University of Turku, Turku, Finland; anne.roivainen@utu.fi.
University of Turku · FITurku PET Centre · FIAmsterdam University Medical Centers · NLTurku University Hospital · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bexmarilimab is a new humanized monoclonal antibody against common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1) and is in clinical trials for macrophage-guided cancer immunotherapy. In addition being associated with cancer, CLEVER-1 is also associated with fibrosis. To facilitate prospective human PET studies, we preclinically evaluated

Indexed as

Kidney DiseasesNeoplasmsAnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedCell Adhesion Molecules, NeuronalCell Line, TumorDeferoxamineFibrosisHumansPositron-Emission TomographyPositron Emission Tomography Computed TomographyProspective StudiesRabbitsRadioisotopesReceptors, Lymphocyte HomingAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedbexmarilimabCell Adhesion Molecules, NeuronalDeferoxamineRadioisotopesReceptors, Lymphocyte HomingZirconium89ZrbexmarilimabCLEVER-1PET/CTrenal fibrosiswhole-body distribution

Identifiers

PMID36302655
PMCPMC10071790
OpenAlexW4307501618

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.